De-Risked Development Path £10 Target8 Apr 2026 14:21
FARN De-Risked Development Path and Strong #BEXMAB Efficacy Drive Reiterated Buy on Faron and £10 Target
Faron Pharmaceuticals Oy, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a £10.00 price target.